Skip to main content
Premium Trial:

Request an Annual Quote

Deloitte Consulting Buys Analytics Firm Recombinant Data

NEW YORK (GenomeWeb News) – Deloitte Consulting late on Tuesday announced it has acquired Recombinant Data for an undisclosed amount.

Based in Newton, Mass., Recombinant Data provides healthcare IT solutions and research data management and analytics. Its products and services, Deloitte Consulting said, are used to advance personalized medicine, translational research — including genomics, phenomics, and proteomics — and healthcare performance management.

Its services allow academic medical centers, federal agencies, and life science firms to "conduct translational research and analyze phenomic, genomic, and biobanking data in pursing personalized and evidence-based medicine," Deloitte Consulting said. "These solutions can help clients unlock the underlying power of digital data."

The deal, Recombinant Data added, will accelerate its product development, sales, and staffing, while expanding Deloitte Consulting's footprint in Boston.

The business will be incorporated within Deloitte Consulting Innovation under the name Recombinant by Deloitte. Recombinant Data, Deloitte Consulting said, has seen "significant" year-over-year growth since its founding in 2005.

"Joining forces with Recombinant represents a bold move around innovation that will open new horizons for Deloitte in the life sciences and healthcare sectors,” Andrew Vaz, principal and chief innovation officer of Deloitte Consulting, said in a statement. "It will extend the Deloitte brand into hybrid business models in which world-class services are combined with advanced intellectual property assets."

Deloitte Consulting is a subsidiary of Deloitte.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.